Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

Socinski, Mark A.; Zhang, C.; Herndon, James E.; Dillman, Robert O.; Clamon, Gerald H.; Vokes, Everett E.; Akerley, Wallace; Crawford, Jeffrey; Perry, Michael C.; Seagren, Stephen L.; Green, M. R.

doi:10.1093/annonc/mdh282

Cited by 64 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, dose escalation is limited by normal tissue toxicity, particularly of the lung. Attempts to increase dose above lung tolerance have been associated with increased radiation-induced pneumonitis [4,5], while concomitant chemotherapy is associated with increased oesophagitis [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

The Use of the Active Breathing Coordinator Throughout Radical Non–Small-Cell Lung Cancer (NSCLC) Radiotherapy

Brock

McNair

Panakis

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The Use of the Active Breathing Coordinator Throughout Radical Non–Small-Cell Lung Cancer (NSCLC) Radiotherapy

Brock

McNair

Panakis

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…The addition of sequential or concomitant cisplatin-based chemotherapy to RT improves survival by 4-5% at 2 years. Concomitant treatment, however, is associated with an increased risk of radiation-induced oesophageal toxicity [6][7][8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

Defining the margins in the radical radiotherapy of non-small cell lung cancer (NSCLC) with active breathing control (ABC) and the effect on physical lung parameters

Panakis

McNair

Christian

et al. 2008

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…In addition, the expectations for long-term benefits may be limited on the part of physicians, as well as on the part of the patients or their families. Therefore, the number of clinical trials designed to specifically study the treatment of elderly patients with stage III NSCLC is limited (17,18).…”

Section: Discussionmentioning

confidence: 99%

Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients

Takeshita

Masago

Fujita

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Elderly patients with stage III non-small-cell lung cancer (NSCLC) are frequently underrepresented in clinical trials that evaluate chemoradiotherapy, due to their poor functional status, coexisting illnesses and limited life expectancy. The Japan Clinical Oncology Group 0301 trial (JCOG0301) was the first study to demonstrate that thoracic radiation therapy (TRT) with daily low-dose carboplatin may improve the outcome of elderly patients with stage III NSCLC. However, the efficacy and safety profiles of chemoradiotherapy, including platinum doublets, have not been clearly determined in this patient population. We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged ≥75 years with previously untreated locally advanced NSCLC. Between February, 2004 and July, 2013, we collected the data of 20 patients treated with weekly paclitaxel and carboplatin for 6 weeks and concurrent TRT. The objective response rate was 90%, the disease control rate was 95%, the median progression-free survival was 8.63 months [95% confidence interval (CI): 5.7-16.7] and the median overall survival (OS) was 16.1 months (95% CI: 10.7-41.6). There were no grade 4 hematological or non-hematological toxicities and no reported treatment-related deaths. Therefore, platinum doublet therapy in combination with TRT did not provide a clinically significant survival benefit in our population of elderly patients with locally advanced NSCLC. However, the present study demonstrated the good feasibility and safety of this regimen. Further prospective clinical trials are required to evaluate the efficacy and safety of platinum doublet with TRT in elderly patients.

show abstract

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

Abstract: Baseline hemoglobin and PS, as well as the use of CMT, have the greatest effect on survival in unresectable stage III NSCLC. The use of concurrent chemoradiation increases the risk of esophagitis, which remains the primary radiation-related toxicity.

Cited by 64 publications

References 34 publications

The Use of the Active Breathing Coordinator Throughout Radical Non–Small-Cell Lung Cancer (NSCLC) Radiotherapy

The Use of the Active Breathing Coordinator Throughout Radical Non–Small-Cell Lung Cancer (NSCLC) Radiotherapy

Defining the margins in the radical radiotherapy of non-small cell lung cancer (NSCLC) with active breathing control (ABC) and the effect on physical lung parameters

Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients

Contact Info

Product

Resources

About